MedPath

Evaluation of the efficacy of Methylphenidate and modafinil in the treatment of excessive daily sleepiness in patients with drug-resistant epilepsy and comparison with the control group

Phase 1
Recruiting
Conditions
Epilepsy.
Epilepsy and recurrent seizures
Registration Number
IRCT20171030037093N22
Lead Sponsor
Esfahan University of Medical Sciences
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
All
Target Recruitment
84
Inclusion Criteria

People with refractory epilepsy
Diagnosis of EDS by a neurologist
Hypersensitivity to methylphenidate and modafinil
Individual consent to participate in the study

Exclusion Criteria

Head trauma
Diagnosis of other neurologic diseases such as dementia
stroke
Thyroid diseases
Drug abuse
Liver or kidney failure

Study & Design

Study Type
interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
The amount of drowsiness. Timepoint: Before and after treatment. Method of measurement: questionnaire.
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath